glp 1 and heart Bridging the gap between GLP1-receptor agonists cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology GLP-1 Agonists in Cardiovascular Diseases:

Among these, BPC-157 and TB-500 have emerged as compounds of growing clinical and research interest due to their multifaceted therapeutic applications in tissue regeneration and cytoprotection

After subcutaneous tumor formation, mice were randomly divided into several groups and treated with different drugs via intraperitoneal injection, including the control group (DMSO), KU-57788 (10 mg/kg), KU-57788 (20 mg/kg), RSL3 (2.5 mg/kg), and a combination group (KU-57788 10 mg/kg + RSL3 2.5 mg/kg)

SIRT1/3 activation by resveratrol attenuates acute kidney injury in a septic rat model

Results are not immediate, but may be visible in a short period of time

[DOI] [PubMed] [Google Scholar] 96.Weir R.L., Hruska R.E